If you wake up one morning and find your muscle and knee joints stiff, and these symptoms even keeps for days in a row, then watch out: you may have got a disease called Rheumatoid Arthritis (or RA). This disease is horrible as it may lead to frequently joints warmness, redness, swollenness, pain and tenderness. Other symptoms may include:
- Poor appetitle;
- Loss of energy
A daunting fact about RA is that no proven cause of rheumatoid arthritis has been specified. Except for the long suspected infectious agents like viruses, fungi and bacteria, genetic inherit is partially to be blamed. This is grounded by the findings that certain genes have been identified likely to increase the risk for getting RA.
Despite the unknown cause mentioned above, there is also no specific drug or meditation to cure RA. The efforts, up to date, are to reduce the inflammation and pain caused by RA and slow the joint destruction and dysfunction. Treatment in the early stages are said to achieve better outcomes.
According to recent report, peficitinib, known as a novel JAK inhibitor, is effective to treat RA and is also well-tolerated in patients. Peficitinib belongs to the inhibitor family and its inhibitor sister tofacitinib has already been approved the treatment of RA in the United States. While as to inhibitor, we have to talk more about it. Inhibitors are usually small molecules and by definition, they are a well-established class of potential useful drugs to be applied in all kinds of fields of medical and pharmaceutical researches, such as neurological disease, cancer, inflammation, metabolic disease and so on.
Based on relevant researches, novel therapeutic agents such as peficitinib are extraordinarily applicable to patients with refractory rheumatoid arthritis, especially for those who have tried other treatments before and without the use of methotrexate at the same time.
Peficitinib is recommended to be taken orally on the daily basis and once per day is enough. As to the dosage, normally 75mg to 150mg would achieve the most significant desired effects in patients with moderate to severe RA. Peficitinib even may surpass placebo in regards to safety and efficacy among patients.
It is also suggested that RA patients with elevated C-reactive protein levels may respond better to higher doses of peficitinib, compared with those who have elevated sedimentation rates.
All in all, we know that peficitinib, also known as ASP015K and JNJ-54781532, has the potential to demonstrate JAK1/3-mediated immunomodulatory effects without the occurrence of JAK2-mediated hematopoietic effects. ASP015K may have potential use in prevention of rejection in solid organ transplantation; treatment of psoriasis; treatment of rheumatoid arthritis.